Brent Page Lab
UBC Pharmaceutical Sciences
At the interface of chemical biology and drug discovery
Recent Publications
P. Iliev*, C. McCutcheon*, T.H. Admas*, A. Reithmeier, M. C. Lopez-McDonald, A. van Outryve, D. Hanke*, J. I. Brown*, M. Haraldsson, R. A. Toillon, D. A. Frank, B. D.G Page‡. Challenging the ‘undruggable’ - targeting STAT3, but identifying potent TrkA-targeted inhibitors. J. Med. Chem. 2025, 68 (9).
D. Hanke*, C. McCutcheon*, B. D. G. Page‡. The Development of Selective Chemical Probes for Serine Arginine Protein Kinase 3. Chem. Biol. Drug Des., 2025, 105 (4), e70101. (IF: 3.2).
N .C.K. Valerie†‡*, K. Sanjiv, O. Mortusewicz, S.M. Zhang, A. Rasti, M. Langelier, D. Rehling, A. Throup, M. Desroses*, P. Wakchaure, I. Almlöf, S. Alam, J. Boström, L. Bevc, P. Stenmark, J.M. Pascal, T. Helleday, B.D.G. Page, M. Altun. Coupling cellular target engagement to drug-induced responses with CeTEAM, Nat. Commun., 2024, 15, 10347. (IF = 16.6, citations: 4)
P. P. Adhikary, T. Idowu*, Z. Tan, C. Hoang*, M. Dumbani, L. Mappalakayil, J. Weiner, D. Beule, G. Wolber, B. D. G Page‡, S. Hedtrich‡: Disrupting TSLP – TSLP receptor interactions via small molecule inhibitors yields a novel and efficient treatment option for atopic diseases, EMBO Mol. Med., 2024, 16 (7), 1630. (IF = 9.0, citations: 4).
J. Qian, Y. Ma, W. Tahaney, C. Moyer, A. Lanier, J. Hill, D. Coleman, N. Koupaei, S. G. Hilsenbeck, B. D. G Page, A. Mazumdar, P. H. Brown‡. The Novel Phosphatase NUDT5 is a Critical Regulator of Triple-Negative Breast Cancer Growth, Breast Cancer Res. 2024, 26 (1), 23. (IF: 6.47)
J. I. Brown*, R. Persaud*, P. Iliev*, U. Karmacharya*, S. Attarha*, H. Sahile*, J. E. Olsen*, D. Hanke*, T. Idowu*, D. A. Frank, A. Frankel, K. C. Williams, and B. D. G. Page‡, Revisiting Pyrimethamine to optimize its therapeutic potential as a cancer therapy. Eur. J. Med. Chem. 2024, 264, 115971. (IF: 6.70)
R. A. Prout-Holm*, C. C van Walstijn, A. Hitsman, M. J. Rowley, J. E. Olsen*, B. D. G. Page‡, A. Frankel‡, Evaluating Interactions Between Small Molecules and their Biological Targets Using the Isothermal Ligand-Induced Resolubilization Assay (ILIRA). ChemBioChem, 2024, e202300773. (IF: 3.2)
J.I. Brown†*, P. Wang, A.Y.L. Wong, B. Petrova, R. Persaud*, S. Soukhtehzari, M.L. McDonald, D. Hanke*, J. Christensen*, P. Iliev*, W. Wang, D. K. Everton*, K.C. Williams, D.A. Frank, N. Kanarek, B.D.G. Page‡. Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity. Metabolites 2023, 13(2): 151 (IF: 5.581).
L.N. Heppler†, S. Attarha*, J.I. Brown*, R. Persaud*, P. Wong, B. Petrova, I. Tosic, F.B. Burton, Y. Flamand, S.R. Walker, J.E. Yeh, R.A. Zubarev, M. Gaetani, N. Kanarek, B.D.G. Page, D.A. Frank. The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. J. Biol. Chem. 2022, 298(2): 101531 (IF:5.157).
A. Nguyen†, P. Chao, C.Y. Ong, E. Rouhollahi, N. AL Fayez, L. Lin, J. Brown*, R. Böttger, B.D.G. Page, H. Wong, S. D. Li‡. Chemically Engineering the Drug Release Rate of a PEG-Paclitaxel Conjugate using Click and Steric Hindrance Chemistries for Optimal Efficacy. Biomaterials. 2022, 289: 12173 (IF: 15.304).
P. Iliev†*, D. Hanke†*, B.D.G. Page‡. STAT Protein Thermal Shift Assays to Monitor Protein-Inhibitor Interactions. ChemBioChem 2022, 23: e39 (IF: 3.164).
See the full list via Google Scholar (email Brent to request a copy of any of our articles)